Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005

References

• Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002; 90: 162–73
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Taylor M, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007; 57: 43–66
   PubMed Web of Science ®Google Scholar
• National Board of Health and Welfare. Cancer incidence in Sweden 2005. Available from:, , www.socialstyrelsen.se/Statistik/statistik_amne/Cancer.
   Google Scholar
• National Board of Health and Welfare. Causes of death 2004. Available from:, , www.socialstyrelsen.se/NR/rdonlyres/DACE2C01-189F-4DA2-99EC-EC1010E559CE/7110/2007422.pdf.
   Google Scholar
• National Center for Health Statistics. The personal number system of Sweden, Norway, Denmark and Israel. In: AS Lunde, Vital and health statistics, Series 2, No. 84. Washington, D.C: Government Printing Office; 1980.
   Google Scholar
• Sekretesslagen. 1980: 100, http://www.riksdagen.se/webbnav/index.aspx?nid=3911&bet=1980:100.
   Google Scholar
• Datainspektionen Nationella kvalitetsregister. [The Swedish Data Inspection Board, National quality registers.], Report No. 2002:1. 2002. Available from: www.datainspektionen.se/pdf/rapporter/nationella_kvalitetsregister.pdf.
   Google Scholar
• Gleason DF. Histologic grading and clinical staging of carcinoma of the prostate. Urologic pathology, M Tannenbaum. Lea & Febiger, Philadelphia, PA 1977; 171–98
   Google Scholar
• Mostofi, FK, Sesterhenn, IA, Sobin, LH. Histological typing of prostate tumours. International Classification of Tumours No. 22. GenevaSwitzerland: WHO; 1980.
   Google Scholar
• Egevad L. Reproducibility of Gleason grading of prostate cancer can be improved by the use of reference images. Urology 2001; 57: 291–5
   PubMed Web of Science ®Google Scholar
• Mattsson, B. The completeness of registration in the Swedish Cancer Register, Report No. 15. StockholmSweden: Stat Rep HS; 1977.
   Google Scholar
• Sandblom G, Dufmats M, Olsson M, Varenhorst E. Validity of a population-based cancer register in Sweden—an assessment of data reproducibility in the South-East Region Prostate Cancer Register. Scand J Urol Nephrol 2003; 37: 112–9
   PubMed Web of Science ®Google Scholar
• Penson, DF, Chan, JM, and the Urologic Diseases in America Project. Prostate cancer. J Urol. 2007;177:2020–9.
   Google Scholar
• Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling JE. Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys 1996; 34: 33–9
   PubMed Web of Science ®Google Scholar
• Swanson GP, Thompson IM, Basler J. Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer 2006; 107: 439–50
   PubMed Web of Science ®Google Scholar
• Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber J-E, Hellström M, et al. The national Prostate Cancer Register in Sweden 1998–2002: trends in incidence, treatment and survival. Scand J Urol Nephrol 2005; 39: 117–23
   PubMed Web of Science ®Google Scholar
• Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546–51
   PubMed Web of Science ®Google Scholar
• Thompson I, Trasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guide-line for the management of clinically localized prostate cancer: 2007 an update. J Urol 2007; 177: 2106–31
   PubMed Web of Science ®Google Scholar
• Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders M, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 1248–53
   PubMedGoogle Scholar
• Socialstyrelsen. In patient operations in Sweden, 2007. Available from:, , 192.137.163.40/epcfs/FisFrameSet.asp?FHStart=ja&W=1280&H=1024.
   Google Scholar
• Sandblom G, Mattsson E, Nilsson J, Damber JE, Johansson JE, Lundgren R, et al. Prostate cancer registration in four Swedish regions 1996— differences in incidence, age structure and management. Scand J Urol Nephrol 1999; 33: 306–11
   PubMed Web of Science ®Google Scholar
• Sandblom, G, Dufmats, M, Nordenskjöld, K, Varenhorst, E. Prostate carcinoma trends in three counties in Sweden 1987–1996: results from a population-based national cancer register. South-East Region Prostate Cancer Group., Cancer 2000;88:1445–53.
   PubMed Web of Science ®Google Scholar
• Sandblom G, Carlsson P, Sigsjo P, Varenhorst E. Pain and health-related quality of life in a geographically defined population of men with prostate cancer. Br J Cancer 2001; 85: 497–503
   PubMed Web of Science ®Google Scholar
• Sandblom, G. Diagnosis, management, quality of life, and long-term survival in prostate cancer patients: a study based on national, regional, and local cancer register data in Sweden. LinköpingSweden: Linköping University; 2001.
   Google Scholar
• Sandblom G, Holmberg L, Damber JE, Hugosson J, Johansson JE, Lundgren R, et al. Prostate-specific antigen as surrogate for characterizing prostate cancer subgroups. Scand J Urol Nephrol 2002; 36: 106–12
   PubMed Web of Science ®Google Scholar
• Sandblom G, Holmberg L, Damber JE, Hugosson J, Johansson JE, Lundgren R, et al. Prostate-specific antigen for prostate cancer staging in a population-based register. Scand J Urol Nephrol 2002; 36: 99–105
   PubMed Web of Science ®Google Scholar
• Stattin P, Johansson R, Damber JE, Hellstrom M, Hugosson J, Lundgren R, et al. Non-systematic screening for prostate cancer in Sweden—survey from the National Prostate Cancer Register. Scand J Urol Nephrol 2003; 37: 461–5
   PubMed Web of Science ®Google Scholar
• Sennfalt K, Carlsson P, Thorfinn J, Frisk J, Henriksson M, Varenhorst E. Technological changes in the management of prostate cancer result in increased healthcare costs—a retrospective study in a defined Swedish population. Scand J Urol Nephrol 2003; 37: 226–31
   PubMed Web of Science ®Google Scholar
• Aus G, Nordenskjold K, Robinson D, Rosell J, Varenhorst E. Prognostic factors and survival in node-positive (N1) prostate cancer—a prospective study based on data from a Swedish population-based cohort. Eur Urol 2003; 43: 627–31
   PubMed Web of Science ®Google Scholar
• Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study (CAPS). Cancer Res 2004; 64: 2918–22
   PubMed Web of Science ®Google Scholar
• Wiklund F, Jonsson BA, Brookes AJ, Stromqvist L, Adolfsson J, Emanuelsson M, et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 2004; 10: 7150–6
   PubMed Web of Science ®Google Scholar
• Sun J, Hedelin M, Zheng SL, Adami HO, Bensen J, Augustsson-Balter K, et al. Interleukin-6 sequence variants are not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13: 1677–9
   PubMed Web of Science ®Google Scholar
• Sennfält K, Sandblom G, Carlsson P, Varenhorst E. Costs and effects of prostate cancer screening in Sweden—a 15-year follow-up of a randomized trial. Scand J Urol Nephrol 2004; 38: 291–8
   PubMed Web of Science ®Google Scholar
• Sennfält K, Carlsson P, Sandblom G, Varenhorst E. The estimated economic value of the welfare loss due to prostate cancer pain in a defined population. Acta Oncol 2004; 43: 290–6
   PubMed Web of Science ®Google Scholar
• Sandblom G, Varenhorst E, Löfman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 2004; 46: 717–23
   PubMed Web of Science ®Google Scholar
• Sandblom G, Carlsson P, Sennfält K, Varenhorst E. A population-based study of pain and quality of life during the year before death in men with prostate cancer. Br J Cancer 2004; 90: 1163–8
   PubMed Web of Science ®Google Scholar
• Lindmark F, Zheng SL, Wiklund F, Bensen J, Balter KA, Chang B, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004; 96: 1248–54
   PubMed Web of Science ®Google Scholar
• Jonsson BA, Adami HO, Hagglund M, Bergh A, Göransson I, Stattin P, et al. –160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer 2004; 109: 348–52
   PubMed Web of Science ®Google Scholar
• Chang, ET, Hedelin, M, Adami, HO, Grönberg, H, Balter, KA. Re: Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst. 2004;96:1108; author reply 1108–9.
   Google Scholar
• Xu, J, Lowey, J, Wiklund, F, Sun, J, Lindmark, F, Hsu, FC, et al. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:2563–8.
   PubMed Web of Science ®Google Scholar
• Sun J, Wiklund F, Zheng SL, Chang B, Balter K, Li L, et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005; 97: 525–32
   PubMedGoogle Scholar
• Stattin P, Johansson R, Lodnert R, Andren O, Bill-Axelsson A, Bratt O, et al. Geographical variation in incidence of prostate cancer in Sweden. Scand J Urol Nephrol 2005; 39: 372–9
   PubMed Web of Science ®Google Scholar
• Sennfält, K. Economic studies of health technology changes in prostate cancer care. Linköping, Sweden: Center for Medical Technology Assessment, Department of Health and Society, Linköping University; 2005.
   Google Scholar
• Lindstrom S, Wiklund F, Jonsson BA, Adami HO, Bälter K, Brookes AJ, et al. Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. Hum Genet 2005; 118: 339–47
   PubMed Web of Science ®Google Scholar
• Lindmark F, Zheng SL, Wiklund F, Bälter KA, Sun J, Chang B, et al. Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer 2005; 93: 493–7
   PubMed Web of Science ®Google Scholar
• Chang ET, Hedelin M, Adami HO, Grönberg H, Bälter KA. Alcohol drinking and risk of localized versus advanced and sporadic versus familial prostate cancer in Sweden. Cancer Causes Control 2005; 16: 275–84
   PubMed Web of Science ®Google Scholar
• Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E. Survival in prostate carcinoma—outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Register of Sweden. Cancer 2005; 103: 943–51
   PubMed Web of Science ®Google Scholar
• Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu FC, et al. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemol Biomarkers Prev 2005; 14: 2563–8
   PubMed Web of Science ®Google Scholar
• Varenhorst E, Garmo H, Holmberg L, Stattin P, Johansson J-E. Prostatacancer i Sverige 1998–2003. Drastisk förändring av sjukdomspanoramat. Läkartidningen 2006; 5: 285–8
   Google Scholar
• Robinson D, Aus G, Bak J, Gorecki T, Herder A, Rosell J, et al. Long-term follow-up of conservatively managed incidental carcinoma of the prostate: a multivariate analysis of prognostic factors. Scand J Urol Nephrol 2007; 41: 103–9
   PubMed Web of Science ®Google Scholar